Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Coswig – page 50

1 038 clinical trials in Coswig, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Coswig at a glance
1 038
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 038 trials in Coswig

Open in trial search

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imetelstat Sodium
  • Sponsor:Geron Corp.

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study of Tepotinib for Patients with Advanced Lung Cancer with MET Exon 14 Skipping Alterations or MET Amplification

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tepotinib
  • Sponsor:Merck Healthcare KGaA

B-cell lymphoma

Not recruiting

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:University Of Cologne

Lupus nephritis

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Class III or IV Lupus Nephritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:F. Hoffmann-La Roche AG

IgA nephropathy

Not recruiting

Study on the Effects of Atacicept in Adults with IgA Nephropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Hepatic cirrhosis

Not recruiting

Study on Zibotentan and Dapagliflozin for Patients with Liver Cirrhosis and Portal Hypertension

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Study of Pembrolizumab and Drug Combination for Patients with Advanced Esophageal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Coswig

What the registry says about research in the country

01 Pulmonary Fibrosis Research

Ongoing clinical trials focusing on Progressive Pulmonary Fibrosis (PPF) and Idiopathic Pulmonary Fibrosis (IPF), evaluating innovative inhaled treatments to improve lung function and patient outcomes.

  • Inhaled Treprostinil Studies
  • Long-term Safety Evaluations
  • FVC Measurements

Multiple Phase 3 studies are examining both short and long-term treatment effects in patients with fibrotic conditions.

02 Interstitial Lung Disease Studies

Research initiatives targeting Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), with trials designed to assess new therapeutic approaches for reducing lung function decline.

  • Novel Drug Evaluations
  • Disease Progression Monitoring
  • Treatment Safety Assessments

Comprehensive studies examining both established and experimental treatments for various forms of lung fibrosis.

03 Advanced Therapeutic Development

Investigation of new compounds including bexotegrast and other innovative medications for treating various forms of pulmonary fibrosis and related conditions.

  • Placebo-controlled Studies
  • Efficacy Measurements
  • Long-term Treatment Effects

Multiple parallel studies are evaluating different therapeutic approaches to address various manifestations of fibrotic lung disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.